MAP2K7 and RASopathy: Regarding other RASopathies, the MEK inhibitor selumetinib was approved by the Food and Drug Administration (FDA) in 2020 for the treatment of children with NF1 who have symptomatic, inoperable plexiform neurofibromas [33].